{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-26-000015","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.955530+00:00","generated_at":"2026-05-15T03:05:30.393519+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M","bullets":["Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.","Cash, equivalents, and investments total $143.4M as of March 31, 2026.","Launched Iterative Mapping Early Access Program; Baylor College of Medicine first customer for Tau proteoform assay in NIH-funded cancer study.","Appointed Amber Faust as VP of Global Sales, a commercial leader from Olink and SomaLogic."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-26-000015","json":"https://secwatch.observer/filing/0001808805-26-000015.json","markdown":"https://secwatch.observer/filing/0001808805-26-000015.md","text":"https://secwatch.observer/filing/0001808805-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/0001808805-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/naut-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:05:30.393519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cce7777df9d9911b93b2db8ebcc55a3a3d2a868","claim":"Nautilus Biotechnology, Inc. reported the quarter ended March 31, 2026 results: net income $14.7 million.","evidence_excerpt":"Net loss was $14.7 million for the first quarter of 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/0001808805-26-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$14.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}